Entorhinal cortex vulnerability to human APP expression promotes hyperexcitability and tau pathology

Affiliations
  • 1Department of Cell Biology, Emory University School of Medicine, Atlanta, GA, USA.
  • 2GDBBS Graduate Program, Laney Graduate School, Emory University, Atlanta, GA, USA.
  • 3Department of Neurology, Yale University, New Haven, CT, USA.
  • 4Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA.
  • 5Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.
  • 6Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA.
  • 7Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, GA, USA.
  • 8Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.
  • 9Department of Neurology, Yale University, New Haven, CT, USA. srikant.rangaraju@yale.edu.
  • 10Department of Cell Biology, Emory University School of Medicine, Atlanta, GA, USA. mjrowan@emory.edu.
  • 11Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, GA, USA. mjrowan@emory.edu.

|

Abstract

Preventative treatment for Alzheimer’s Disease (AD) is dire, yet mechanisms underlying early regional vulnerability remain unknown. In AD, one of the earliest pathophysiological correlates to cognitive decline is hyperexcitability, which is observed first in the entorhinal cortex. Why hyperexcitability preferentially emerges in specific regions in AD is unclear. Using regional, cell-type-specific proteomics and electrophysiology in wild-type mice, we uncovered a unique susceptibility of the entorhinal cortex to human amyloid precursor protein (hAPP). Entorhinal hyperexcitability resulted from selective vulnerability of parvalbumin (PV) interneurons, with respect to surrounding excitatory neurons. This effect was partially replicated with an APP chimera containing a humanized amyloid-beta sequence. EC hyperexcitability could be ameliorated by co-expression of human Tau with hAPP at the expense of increased pathological tau species, or by enhancing PV interneuron excitability in vivo. This study suggests early interventions targeting inhibitory neurons may protect vulnerable regions from the effects of APP/amyloid and tau pathology.